Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Business Wire India Topline data expected in the second half of 2021 Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and…